Background: SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. in silico analysis reveals 4 UTR-SNPs located in the 3 -UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer.SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).
Positive Control: Antibody has been tested on mouse heart lysate.
Immunogen: Synthetic peptide derived from the human SPARC protein.
Purification Method: Antigen Immunoaffiinity Purification
Concentration: See vial for concentration
Formulation: Provided as ligand affinity purified antibody in phosphate buffered saline with 0.08% sodium azide
References: 1. Shi Q, et al. 'Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.' Oncogene. 2007 Jan 8; [Epub ahead of print] PMID: 17213807 2. Aouacheria A, et al. 'In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.' BMC Genomics. 2007 Jan 3;8(1):2 [Epub ahead of print] PMID: 172019113. Xue LY, et al. 'Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.'BMC Cancer. 2006 Dec 22;6(1):296 [Epub ahead of print] PMID: 171876594. Arp HP, et al. 'Predicting the partitioning behavior of various highly fluorinated compounds.' Environ Sci Technol. 2006 Dec 1;40(23):7298-304. PMID: 17180981 5. Kelly KA, et al. 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration.' J Leukoc Biol. 2006 Dec 18; [Epub ahead of print] 6. Markovic, S., et al. 'Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.' J. Clin. Oncol. 2010, Vol. 28, No. 15, 85787. Weiss, G.J., et al. 'Molecular characterization of interdigitating dendritic cell sarcoma.' Rare Tumors, 2010, 2:e508. Alonso, E.N., et al. ‘Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells.’ J. Med. Food., 16, 602-617 (2013).
UniProt: P09486
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
